R

oivant, the biotech cephalopod out to weave blockbusters out of pharma’s discard pile, just brought in a superlative amount of money. But for a young firm that has raised both eyebrows and hackles around the industry, the most important detail about its new investment might be the timing.

Roivant, founded and steered by the 32-year-old former hedge fund manager Vivek Ramaswamy, is today $1.1 billion richer thanks to an investor syndicate led by SoftBank, a Japanese telecommunications giant with a $100 billion investment fund.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine